Knock-down of ubiquitin-specific protease 22 by micro-RNA interference inhibits colorectal cancer growth

International Journal of Colorectal Disease

Volumn 27, Issue 1, 2012, Pages 21-30

  Xu, Hui ^a   Liu, Yan Long ^a   Yang, Yan Mei ^a   Dong, Xin Shu ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Colorectal cancer; HCT116; Micro RNA interference; MVP; USP22

Indexed keywords

LUNG RESISTANCE PROTEIN; MESSENGER RNA; MICRORNA; PROTEINASE; UBIQUITIN SPECIFIC PROTEASE 22; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE G0 PHASE; CELL PROLIFERATION; CELL STRAIN HCT116; CELL VIABILITY; COLORECTAL CANCER; CONTROLLED STUDY; DOWN REGULATION; G1 PHASE CELL CYCLE CHECKPOINT; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; ONCOLOGICAL PARAMETERS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA INTERFERENCE; TUMOR VOLUME; TUMOR WEIGHT; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL NEOPLASMS; DOWN-REGULATION; G1 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HCT116 CELLS; HUMANS; MICE; MICE, NUDE; MICRORNAS; RNA INTERFERENCE; S PHASE; THIOLESTER HYDROLASES; TRANSFECTION; VAULT RIBONUCLEOPROTEIN PARTICLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84863115549     PISSN: 01791958     EISSN: 14321262     Source Type: Journal    
DOI: 10.1007/s00384-011-1275-8     Document Type: Article

References (19)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007) Cancer statistics. CA Cancer J Clin 57:43-66
2. Glinsky GV (2005) Death-from-cancer signatures and stem cell contribution to metastatic cancer. Cell Cycle 4:1171-1175 (Pubitemid 41365385)
3. Glinsky GV, Berezovska O, Glinskii AB (2005) Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 115:1503-1521 (Pubitemid 40814659)
4. Widschwendter M, Fiegl H, Egle D, Mueller-Holzner E, Spizzo G, MarthC WDJ, Campan M, Young J, Jacobs I, Laird PW (2007) Epigenetic stem cell signature in cancer. Nat Genet 39:157-158 (Pubitemid 46184343)
5. Zhang XY, Pfeiffer HK, Thorne AW, McMahon SB (2008) USP22, an hSAGA subunit and potential cancer stem cell marker, reverses the polycomb-catalyzed ubiquitylation of histone H2A. Cell Cycle 7:1522-1524 (Pubitemid 351881314)
6. Zhang XY, Varthi M, Sykes SM, Phillips C, Warzecha C, Zhu W, Wyce A, Thorne AW, Berger SL, McMahon SB (2008) The putative cancer stem cell marker USP22 is a subunit of the human SAGA complex required for activated transcription and cell-cycle progression. Mol Cell 29:102-111
7. Lee HJ, Kim MS, Shin JM, Park TJ, Chung HM, Baek KH (2006) The expression patterns of deubiquitinating enzymes, USP22 and Usp22. Gene Expr Patterns 6:277-284
8. Baek KH (2003) Conjugation and deconjugation of ubiquitin regulation the destiny of proteins. Exp Mol Med 35:1-7
9. Glickman MN, Ciechanover A (2002) The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 82:373-428 (Pubitemid 34654457)
10. Zhao Y, Lang G, Ito S, Bonnet J, Metzger E, Sawatsubashi S, Suzuki E, Le Guezennec X, Stunnenberg HG, Krasnov A, Georgieva SG, Schüle R, Takeyama K, Kato S, Tora L, Devys D (2008) A TFTC/STAGA module mediates histone H2A and H2B deubiquitination, coactivates nuclear receptors, and counteracts heterochromatin silencing. Mol Cell 29:92-101
11. Pijnappel WW, Timmers HT (2008) Dubbing SAGA unveils new epigenetic crosstalk. Mol Cell 29:152-154 (Pubitemid 351181281)
12. Scheper RJ, Scheffer GL, Flens MJ, van der Valk P, Meijer CJLM, Pinedo HM, Clevers HC, Slovak ML, Rome LH, Shoemaker RH, lzquierdo MA (1996) Role of LRP/major vault protein in multidrug resistance. In: Gupta S, Tsuruo T (eds) Multidrug resistance in cancer cells. Wiley, Chichester, pp. 109-118
13. Scheper RJ, Broxterman HJ, Scheffer GL, Kaaijk P, Dalton WS, Heijningen TH, Kalken CK, Slovak ML, Vries EG, Valk P, Meijer CJLM, Pinedo HM (1993) Overexpression of a M(r)110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res 53:1475-1479 (Pubitemid 23113213)
14. Scheffer GL, Wijngaard PLJ, Flens MJ, lzquierdo MA, Slovak ML, Pinedo HM, Meijer CJLM, Clevers HC, Scheper RJ (1995) The drug resistance-related protein LRP is the human major vault protein. Nat Med 1:578-582
15. lzquierdo MA, Shoemaker RH, Flens MJ, Scheffer GL, Wu L, Prather TR, Scheper RJ (1996) Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines. Int J Cancer 65:230-237 (Pubitemid 26051685)
16. Liu YL, Yang YM, Xu H, Dong XS (2010) Increased expression of ubiquitin-specific protease 22 can promote cancer progression and predict therapy failure in human colorectal cancer. J Gastroenterol Hepatol 25:1800-1805
17. Liu YL, Yang YM, Xu H, Dong XS (2011) Aberrant expression of USP22 is associated with liver metastasis and poor prognosis of colorectal cancer. J Surg Oncol 103:283-289
18. Kitazono M, Sumizawa T, Takebayashi Y, Chen ZS, Furukawa T, Nagayama S, Tani A, Takao S, Aikou T, Akiyama S (1999) Multidrug resistance and the lung resistance-related protein in human colon carcinoma SW-620 cells. J Natl Cancer Inst 91:1647-1653 (Pubitemid 29479932)
19. List AF, Spier CS, Grogan TM, Johnson C, Roe DJ, Greer JP, Wolff SN, Broxterman HJ, Scheffer GL, Scheper RJ, Dalton WS (1996) Overexpression of the major vault transporter protein lungresistance protein predicts treatment outcome in acute myeloid leukemia. Blood 87:2464-2469 (Pubitemid 26086891)